Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
Roivant Sciences and subsidiary Priovant’s TYK2/JAK inhibitor brepocitinib—recently approved for an autoimmune skin disease—significantly reduced the need for steroid treatment…